Post-treatment diffusion MRI–derived apparent diffusion coefficient as a biomarker of response and prognosis following definitive radiotherapy for prostate cancer: Impact of focal dose escalation on ADC dynamics

Urologic Oncology: Seminars and Original Investigations · Published 2026-07-01 · DOI 10.1016/j.urolonc.2026.06.024

Authors (6)

Cem Onal, Gurcan Erbay, Ozan Cem Guler, Aysenur Elmali, Birhan Demirhan, Melek Yavuz

Abstract

PubPorta does not have an abstract for this article yet.

Read the article at the publisher →

Publication details

Year

2026

Citation

Onal, C., Erbay, G., Guler, O., et al. (2026). Post-treatment diffusion MRI–derived apparent diffusion coefficient as a biomarker of response and prognosis following definitive radiotherapy for prostate cancer: Impact of focal dose escalation on ADC dynamics. Urologic Oncology: Seminars and Original Investigations. https://doi.org/10.1016/j.urolonc.2026.06.024

Related articles

• Does size matter? A national analysis of patterns of adjuvant immunotherapy receipt and tumor size–dependent survival in pT3N0M0 clear cell renal cell carcinoma · Urologic Oncology: Seminars and Original Investigations · 2026 · Same journal
• Sex-based differences in peri-operative and long-term oncologic outcomes after primary surgical treatment for kidney cancer: A comprehensive analysis from a high-volume tertiary center · Urologic Oncology: Seminars and Original Investigations · 2026 · Same journal
• Universally offered germline testing in upper tract urothelial carcinoma · Urologic Oncology: Seminars and Original Investigations · 2026 · Same journal
• Automated algorithm for surgical outcomes abstraction for cystectomy · Urologic Oncology: Seminars and Original Investigations · 2026 · Same journal
• Beyond PSA90: Deep PSA response predicts outcomes in nonmetastatic CRPC · Urologic Oncology: Seminars and Original Investigations · 2026 · Same journal
• Clinical outcomes of deferred cytoreductive nephrectomy after initial systemic therapy in metastatic renal cell carcinoma: A multicenter retrospective study · Urologic Oncology: Seminars and Original Investigations · 2026 · Same journal
• Association of EVITA with safety in advanced urothelial carcinoma: A multicenter real-world study · Urologic Oncology: Seminars and Original Investigations · 2026 · Same journal
• Featured SUO Fellow: Parth Thakker, MD · Urologic Oncology: Seminars and Original Investigations · 2026 · Same journal
• Identification and validation of TP53/p53 status as a prognostic marker in penile squamous cell carcinoma: Evidence from a cohort study and meta-analysis · Urologic Oncology: Seminars and Original Investigations · 2026 · Same journal
• Geospatial correlation of industrial plastics emissions with bladder and kidney cancer burden in Ohio · Urologic Oncology: Seminars and Original Investigations · 2026 · Same journal